NO953672D0 - Fenoksyfenyleddiksyrederivater - Google Patents

Fenoksyfenyleddiksyrederivater

Info

Publication number
NO953672D0
NO953672D0 NO953672A NO953672A NO953672D0 NO 953672 D0 NO953672 D0 NO 953672D0 NO 953672 A NO953672 A NO 953672A NO 953672 A NO953672 A NO 953672A NO 953672 D0 NO953672 D0 NO 953672D0
Authority
NO
Norway
Prior art keywords
vasospasm
cerebral
asthma
hypertension
chem
Prior art date
Application number
NO953672A
Other languages
English (en)
Other versions
NO953672L (no
Inventor
Scott W Bagley
Theodore P Broten
Prasun K Chakravarty
Daljit S Dhanoa
Kenneth J Fitch
William J Greenlee
Nancy Jo Kevin
Douglas J Pettibone
Ralph A Rivero
James R Tata
Thomas F Walsh
Jr David L Williams
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO953672D0 publication Critical patent/NO953672D0/no
Publication of NO953672L publication Critical patent/NO953672L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO953672A 1993-03-19 1995-09-18 Fenoksyfenyleddiksyrederivater NO953672L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3445593A 1993-03-19 1993-03-19
US19746794A 1994-02-24 1994-02-24
PCT/US1994/002871 WO1994021590A1 (en) 1993-03-19 1994-03-17 Phenoxyphenylacetic acid derivatives

Publications (2)

Publication Number Publication Date
NO953672D0 true NO953672D0 (no) 1995-09-18
NO953672L NO953672L (no) 1995-11-17

Family

ID=26710968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953672A NO953672L (no) 1993-03-19 1995-09-18 Fenoksyfenyleddiksyrederivater

Country Status (23)

Country Link
EP (1) EP0617001B1 (no)
JP (1) JPH08508034A (no)
KR (1) KR960700992A (no)
CN (1) CN1119434A (no)
AT (1) ATE189217T1 (no)
AU (1) AU679710B2 (no)
CA (1) CA2119051A1 (no)
CZ (1) CZ233595A3 (no)
DE (1) DE69422742T2 (no)
DK (1) DK0617001T3 (no)
ES (1) ES2141197T3 (no)
FI (1) FI954404A (no)
GR (1) GR3032643T3 (no)
HR (1) HRP940179B1 (no)
HU (1) HU217028B (no)
IL (1) IL108944A0 (no)
NO (1) NO953672L (no)
NZ (1) NZ263414A (no)
PL (1) PL175786B1 (no)
PT (1) PT617001E (no)
RU (1) RU2139273C1 (no)
SK (1) SK114795A3 (no)
WO (1) WO1994021590A1 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022978A1 (en) * 1995-01-27 1996-08-01 Rhone Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
EP0774965A4 (en) * 1994-08-08 1997-10-29 Merck & Co Inc PHENOXYPHENYLACETIC ACID DERIVATIVES
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
DE19527568A1 (de) 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
AU703486B2 (en) * 1995-12-12 1999-03-25 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
US5688974A (en) * 1995-12-12 1997-11-18 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
ES2241036T3 (es) * 1996-02-02 2005-10-16 MERCK & CO., INC. Procedimiento de tratamiento de diabetes y estados patologicos asociados.
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
SG87051A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Process for preparing biphenyl isoxazole sulfonamide intermediates
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19710831A1 (de) * 1997-03-15 1998-09-17 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
CA2304712C (en) * 1997-09-26 2008-04-29 Knoll Aktiengesellschaft Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
GB9722287D0 (en) * 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
DE19747788A1 (de) 1997-10-29 1999-05-06 Basf Ag Substituierte 2-(2'-Pyridyloxy)phenylessigsäureamide, ihre Herstellung und Verwendung, sowie sie enthaltende Mittel
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
CN1295477A (zh) * 1998-03-31 2001-05-16 田边制药株式会社 排尿困难的预防或治疗剂
US6017918A (en) * 1998-08-06 2000-01-25 Warner-Lambert Company Phenyl glycine compounds and methods of treating atherosclerosis and restenosis
US6284795B1 (en) * 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
WO2001027077A2 (en) * 1999-10-12 2001-04-19 Basf Aktiengesellschaft Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
CA2437118A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
BR0308537A (pt) * 2002-03-20 2005-02-09 Metabolex Inc Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
US8614236B2 (en) 2006-12-12 2013-12-24 University Of Washington Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
CN101042381B (zh) * 2007-04-28 2014-01-08 长春迈灵生物工程有限公司 一种地舍平的检测方法
CA2777455A1 (en) * 2009-11-09 2011-05-12 Novadex Pharmaceuticals Ab Novel 1,3-oxazolidine compounds and their use as renin inhibitors
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
CA2822017C (en) 2010-12-23 2015-04-07 Pfizer Inc. Glucagon receptor modulators
DK2673260T3 (en) 2011-02-08 2016-10-10 Pfizer Glucagonreceptormodulator
MX2014000855A (es) 2011-07-22 2014-04-30 Pfizer Moduladores receptores de glucagon de quinolinilo.
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
CN111825564B (zh) * 2020-09-21 2020-12-29 西藏甘露藏药股份有限公司 一种从渣驯中提取的化合物、制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1408738A (fr) * 1964-04-29 1965-08-20 Nobel Bozel Nouveaux dérivés de l'acide bis(hydroxy-4-phényl)-acétique
US4748272A (en) * 1986-08-01 1988-05-31 Rorer Pharmaceutical Corp. Phenoxyphenylacetates for use as potential modulators of arichidonic acid pathways
JPS63122605A (ja) * 1986-11-10 1988-05-26 Tokuyama Soda Co Ltd 除草剤組成物

Also Published As

Publication number Publication date
JPH08508034A (ja) 1996-08-27
WO1994021590A1 (en) 1994-09-29
KR960700992A (ko) 1996-02-24
PT617001E (pt) 2000-06-30
DE69422742D1 (de) 2000-03-02
IL108944A0 (en) 1994-06-24
NZ263414A (en) 1997-09-22
ATE189217T1 (de) 2000-02-15
AU679710B2 (en) 1997-07-10
HUT73658A (en) 1996-09-30
GR3032643T3 (en) 2000-06-30
EP0617001A1 (en) 1994-09-28
DE69422742T2 (de) 2000-08-17
RU2139273C1 (ru) 1999-10-10
FI954404A0 (fi) 1995-09-18
CN1119434A (zh) 1996-03-27
AU5787894A (en) 1994-09-22
HRP940179A2 (en) 1998-02-28
PL175786B1 (pl) 1999-02-26
DK0617001T3 (da) 2000-04-17
HU217028B (hu) 1999-11-29
HU9502725D0 (en) 1995-11-28
CZ233595A3 (en) 1996-01-17
ES2141197T3 (es) 2000-03-16
EP0617001B1 (en) 2000-01-26
NO953672L (no) 1995-11-17
PL310661A1 (en) 1995-12-27
SK114795A3 (en) 1996-06-05
CA2119051A1 (en) 1994-09-20
FI954404A (fi) 1995-09-18
HRP940179B1 (en) 2000-10-31

Similar Documents

Publication Publication Date Title
FI954404A (fi) Fenoksifenyylietikkahappojohdannaiset
MX9308191A (es) Antagonistas de endotelina.
NO986090L (no) Fenylalaninderivater som integrininhibitorer
EA199800478A1 (ru) N-([1,2,4]триазолазинил)бензолсульфонамиды и пиридинсульфонамиды и их применение в качестве гербицидов
ATE323088T1 (de) Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten
AP9701004A0 (en) Low molecular weight bicyclic thrombin inhibitors.
DE69908648D1 (de) Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
CA2382406A1 (en) Substituted 2-arylbenzazole compounds and their use as antitumour agents
GR3025926T3 (en) Condensed pyrimidine derivatives and their use as angiotensine II antagonists
DE59409833D1 (de) Piperazinderivate
PT1023267E (pt) Compostos de piridilo e composicoes farmaceuticas que os contem
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
DE60203623D1 (de) Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
EE03564B1 (et) Bensotiasiindioksiidid kui endoteliini antagonistid
DK0980374T3 (da) Phosphodiesterase 4-inhiberende diazepinoindoloner.
MX9202191A (es) Antagonistas de endotelina.
PT799221E (pt) Quinazolinas como inibidores da enzima de conversao de endotelina
PL326236A1 (en) Novel compounds - derivatives of sulphonylpyrimidine exhibiting anticarcinogenous effect and method of obtaining them
DK478585A (da) 4-alkoxy-pyrido(2,3-d)pyrimidin-derivater, deres fremstilling og anvendelse
AR012094A1 (es) Derivados de quinolein-2(1h)-ona y de dihidroquinolein-2(1h)-ona, su preparacion y su aplicacion en terapeutica.
ATE86983T1 (de) Acyl-derivate von hydroxy-pyrimidinen.
EA200100151A1 (ru) Производные пиперазинона и их применение
TH49639EX (th) ข้อต่อไม้คิวสนุกเกอร์
RU92016440A (ru) Производные гидрокси- и алкоксипиридинов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application